{"changes":[],"country":"GB","description":"CHARM Therapeutics has developed a menin inhibitor that treats Acute Myeloid Leukemia by reprogramming cancerous cells rather than just killing them. It targets AML patients who develop resistance to existing menin inhibitor treatments. The compound is structurally optimized to bind precisely within the KMT2A interface on menin for more durable resistance results.","domain":"charmtx.com","employees":null,"founded":2021,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech","investors":["khosla","nea"],"lat":51.507446,"lng":-0.127765,"location":"London","name":"CHARM Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":80000000,"currency":"USD","date":"2025-09-02","investors":["khosla","nea"],"leadInvestor":"khosla","source":{"fact":"round","publisher":"vc-portfolio","retrievedAt":"2026-05-13","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"charmtx-com","sources":[{"fact":"round","publisher":"vc-portfolio","retrievedAt":"2026-05-13","status":"attributed","url":null},{"fact":"existence","publisher":"charmtx.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://charmtx.com"},{"fact":"description","publisher":"charmtx.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://charmtx.com"}],"stage":"series-b+","techStack":["Nginx","WordPress 7.0","Lenis 1.1.13","Google Analytics","Google Tag Manager","Slider Revolution","jQuery Migrate 3.4.1","imagesLoaded 4.1.4","parallax.js","PHP","Onsen UI","MySQL"],"totalRaisedUsd":150000000,"updatedAt":"2026-05-13"}